Veligrotug Medicine 04 June 2024 Extended indication Treatment of moderate to severe thyroid eye disease in adults. Therapeutic value No estimate possible yet Total cost Registration phase Registration application pending Product Active substance Veligrotug Domain Chronic immune diseases Reason of inclusion New medicine (specialité) Main indication Eye disorders Extended indication Treatment of moderate to severe thyroid eye disease in adults. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Viridian Portfolio holder Mechanism of action Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Insulin-like growth factor-I receptor antagonists. Fabrikant: Viridian Therapeutics. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date February 2026 Expected Registration March 2027 Orphan drug Yes Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van IHSI-inschatting. Therapeutic value Current treatment options Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT05176639 (THRIVE); NCT06021054 (THRIVE-2); NCT06384547 (STRIVE) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Schildklier.nl Additional remarks Ongeveer 75.000 mensen hebben de ziekte van Graves, 20% daarvan heeft de oogaandoening Graves oftalmopathie. Ongeveer 5% loopt het risico de oogziekte in ernstige vorm te ontwikkelen (3.750). Expected cost per patient per year Cost € < 130,000.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks De kosten zijn mogelijk gelijk aan die van teptrotumumab. De prijs van teprotumumab wordt geschat op €130.000. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks